200,000+ products from a single source!
sales@angenechem.com
Home > Fluorides > 150586-58-6
CAS No: 150586-58-6 Catalog No: AG001MQR MDL No:
Title | Journal |
---|---|
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). | Neurology 20120710 |
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. | Movement disorders : official journal of the Movement Disorder Society 20101015 |
Rigid analogues of the α2-adrenergic blocker atipamezole: small changes, big consequences. | Journal of medicinal chemistry 20101014 |
Santhera licenses novel dyskinesia therapy to Biovail. | Nature reviews. Drug discovery 20091001 |
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. | Movement disorders : official journal of the Movement Disorder Society 20030801 |
© 2019 Angene International Limited. All rights Reserved.